Utility:
| First paper in which HMGCR was used in a routine testing scheme to provide a differential diagnosis of IIM. The potential cost savings (both health and lab economics) for including the testing of anti-HMGCR antibodies was included in the discussion. The highest prevalence of anti-HMGCR antibodies was found in patients with IMNM (31/69, 44.9%) and have a high disease specificity of 99.7%. The prevalence of anti-HMCGR antibodies in IIM patients from different geographies was statistically different, the highest in Canada (1/7, 14.3%e) and France (17/174, 9.8%). The prevalence and titier of anti-HMCGR antibodies was significantly higher in statin users (26.3%, 47.1 units) vs. non-statin users (3.4%, 7.3 units). |